Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results and Conduct Conference Call on Tuesday, February

Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2012 Results
          and Conduct Conference Call on Tuesday, February 26, 2013

PR Newswire

CHESTERBROOK, Pa., Feb. 12, 2013

CHESTERBROOK, Pa., Feb. 12, 2013 /PRNewswire/ --Auxilium Pharmaceuticals,
Inc. (NASDAQ: AUXL), a specialty biopharmaceutical company, will release
results for the fourth quarter and full year 2012 on Tuesday, February 26,
2013 before the opening of the U.S. financial markets. The Company will also
conduct a conference call that day at 10:00 a.m. ET to discuss results and
highlights of the fourth quarter and full year 2012. The presentation slides
to be used during the call will be available on the "For Investors" section of
the Company's web site under the "Presentations" tab beginning at 10 a.m. ET
on Tuesday, February 26, 2013. A web cast of the conference call and the
presentation slides will be available on the "For Investors" section of the
Company's web site under the "Events" tab beginning at 10:00 a.m. ET on
Tuesday, February 26, 2013. A question and answer session will follow the
presentation.

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO )

Mr. Adrian Adams, Chief Executive Officer and President, will host the
conference call.

Conference call details:
Date:                          Tuesday, February 26, 2013
Time:                          10:00 a.m. ET
Dial-in (U.S.):                866-510-0705
Dial-in (International):       617-597-5363
Web cast:                      http://www.auxilium.com
Passcode:                      AUXILIUM
To access an audio replay of the call:
Access number (U.S.):          888-286-8010
Access number (International): 617-801-6888
Replay Passcode #:             92145279

About Auxilium
Auxilium is a specialty biopharmaceutical company with a focus on developing
and marketing products to predominantly specialist audiences. Auxilium markets
Testim® 1% (testosterone gel) for the topical treatment of hypogonadism and
XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult
Dupuytren's contracture patients with a palpable cord in the U.S.
GlaxoSmithKline LLC co- promotes Testim with Auxilium in the U.S. Ferring
International Center S.A. markets Testim in certain countries of the EU and
Paladin Labs Inc. markets Testim in Canada. Pfizer Inc. has marketing rights
for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 46
countries in Eurasia through April 24, 2013; Asahi Kasei Pharma Corporation
has development and commercial rights for XIAFLEX in Japan; and Actelion
Pharmaceuticals Ltd has development and commercial rights for XIAFLEX in
Canada, Australia, Brazil and Mexico. The sBLA for XIAFLEX for the treatment
of Peyronie's disease was submitted to the FDA on November 6, 2012 and has
been accepted for standard review with a PDUFA date of September 6, 2013.
Additionally, collagenase clostridium histolyticum ("CCH") is in phase IIa of
development for the treatment of Frozen Shoulder syndrome (adhesive
capsulitis) and phase Ib of development for the treatment of cellulite
(edematous fibrosclerotic panniculopathy). Auxilium also has rights to pursue
additional indications for CCH.

AUXILIUM SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995
This news release contains forward-looking statements as defined by the
Private Securities Litigation Reform Act of 1995, including statements made
with respect to Auxilium's strategy, progress and timing of development
programs and related trials, the efficacy of its product candidates, the
commercial benefits available to it as a result of its agreements with third
parties, future operations, financial position, future revenues, projected
costs, prospects, plans and objectives of management and other statements
regarding matters that are not historical facts, and involve predictions.
These statements involve known and unknown risks, uncertainties and other
factors that may cause actual results, performance, achievements or prospects
to be materially different from any future results, performance, achievements
or prospects expressed in or implied by such forward-looking statements. In
some cases you can identify forward-looking statements by terminology such as
''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'',
''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'',
''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of
these terms or similar expressions, although not all forward-looking
statements contain these identifying words. Although forward-looking
statements are based on Auxilium's current plans or assessments that are
believed to be reasonable as of the date of this press release, they
inherently involve certain risks and uncertainties. These forward-looking
statements are subject to a number of risks and uncertainties, including those
discussed under ''Risk Factors'' in Auxilium's Annual Report on Form 10-K for
the year ended December 31, 2011, each of Auxilium's Quarterly Reports on Form
10-Q for the three months ended September 30, 2012, June 30, 2012 and March
31, 2012 and Auxilium's preliminary prospectus supplement and Current Report
on Form 8-K, each filed with the Securities and Exchange Commission (the
"SEC") on January 23, 2013. While Auxilium may elect to update the
forward-looking statements made in this news release in the future, Auxilium
specifically disclaims any obligation to do so. Auxilium's SEC filings may be
accessed electronically by means of the SEC's home page on the Internet at
http://www.sec.gov. There may be additional risks that Auxilium does not
presently know or that Auxilium currently believes are immaterial which could
also cause actual results to differ from those contained in the
forward-looking statements.

Contacts:
James E. Fickenscher/CFO
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
jfickenscher@auxilium.com

William Q. Sargent Jr./ VP IR
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
wsargent@auxilium.com

SOURCE Auxilium Pharmaceuticals, Inc.

Website: http://www.auxilium.com
 
Press spacebar to pause and continue. Press esc to stop.